225 related articles for article (PubMed ID: 17541992)
1. Highly potent and selective substrate analogue factor Xa inhibitors containing D-homophenylalanine analogues as P3 residue: part 2.
Stürzebecher A; Dönnecke D; Schweinitz A; Schuster O; Steinmetzer P; Stürzebecher U; Kotthaus J; Clement B; Stürzebecher J; Steinmetzer T
ChemMedChem; 2007 Jul; 2(7):1043-53. PubMed ID: 17541992
[TBL] [Abstract][Full Text] [Related]
2. New substrate analogue inhibitors of factor Xa containing 4-amidinobenzylamide as P1 residue: part 1.
Schweinitz A; Stürzebecher A; Stürzebecher U; Schuster O; Stürzebecher J; Steinmetzer T
Med Chem; 2006 Jul; 2(4):349-61. PubMed ID: 16848746
[TBL] [Abstract][Full Text] [Related]
3. Effective inhibition of experimental metastasis and prolongation of survival in mice by a potent factor Xa-specific synthetic serine protease inhibitor with weak anticoagulant activity.
Banke IJ; Arlt MJ; Mueller MM; Sperl S; Stemberger A; Stürzebecher J; Amirkhosravi A; Moroder L; Krüger A
Thromb Haemost; 2005 Nov; 94(5):1084-93. PubMed ID: 16363253
[TBL] [Abstract][Full Text] [Related]
4. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
Bhunia SS; Roy KK; Saxena AK
J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
[TBL] [Abstract][Full Text] [Related]
5. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.
Rupin A; Mennecier P; Lila C; de Nanteuil G; Verbeuren TJ
Thromb Haemost; 1997 Oct; 78(4):1221-7. PubMed ID: 9364988
[TBL] [Abstract][Full Text] [Related]
6. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
Ewing WR; Becker MR; Manetta VE; Davis RS; Pauls HW; Mason H; Choi-Sledeski YM; Green D; Cha D; Spada AP; Cheney DL; Mason JS; Maignan S; Guilloteau JP; Brown K; Colussi D; Bentley R; Bostwick J; Kasiewski CJ; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
J Med Chem; 1999 Sep; 42(18):3557-71. PubMed ID: 10479288
[TBL] [Abstract][Full Text] [Related]
7. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
[TBL] [Abstract][Full Text] [Related]
8. Tetrahydro-isoquinoline-based factor Xa inhibitors.
Kucznierz R; Grams F; Leinert H; Marzenell K; Engh RA; von der Saal W
J Med Chem; 1998 Dec; 41(25):4983-94. PubMed ID: 9836616
[TBL] [Abstract][Full Text] [Related]
9. Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization.
Choi-Sledeski YM; McGarry DG; Green DM; Mason HJ; Becker MR; Davis RS; Ewing WR; Dankulich WP; Manetta VE; Morris RL; Spada AP; Cheney DL; Brown KD; Colussi DJ; Chu V; Heran CL; Morgan SR; Bentley RG; Leadley RJ; Maignan S; Guilloteau JP; Dunwiddie CT; Pauls HW
J Med Chem; 1999 Sep; 42(18):3572-87. PubMed ID: 10479289
[TBL] [Abstract][Full Text] [Related]
10. A new factor Xa inhibitor (lefaxin) from the Haementeria depressa leech.
Faria F; Kelen EM; Sampaio CA; Bon C; Duval N; Chudzinski-Tavassi AM
Thromb Haemost; 1999 Nov; 82(5):1469-73. PubMed ID: 10595640
[TBL] [Abstract][Full Text] [Related]
11. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
Young RJ; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chan C; Charbaut M; Chung CW; Convery MA; Kelly HA; Paul King N; Kleanthous S; Mason AM; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE
Bioorg Med Chem Lett; 2008 Jan; 18(1):23-7. PubMed ID: 18054228
[TBL] [Abstract][Full Text] [Related]
12. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3.
Dönnecke D; Schweinitz A; Stürzebecher A; Steinmetzer P; Schuster M; Stürzebecher U; Nicklisch S; Stürzebecher J; Steinmetzer T
Bioorg Med Chem Lett; 2007 Jun; 17(12):3322-9. PubMed ID: 17462889
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel, potent, and specific family of factor Xa inhibitors via combinatorial chemistry.
Ostrem JA; al-Obeidi F; Safar P; Safarova A; Stringer SK; Patek M; Cross MT; Spoonamore J; LoCascio JC; Kasireddy P; Thorpe DS; Sepetov N; Lebl M; Wildgoose P; Strop P
Biochemistry; 1998 Jan; 37(4):1053-9. PubMed ID: 9454596
[TBL] [Abstract][Full Text] [Related]
15. Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties.
Qiao JX; King SR; He K; Wong PC; Rendina AR; Luettgen JM; Xin B; Knabb RM; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2009 Jan; 19(2):462-8. PubMed ID: 19046881
[TBL] [Abstract][Full Text] [Related]
16. Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.
Shi Y; O'Connor SP; Sitkoff D; Zhang J; Shi M; Bisaha SN; Wang Y; Li C; Ruan Z; Lawrence RM; Klei HE; Kish K; Liu EC; Seiler SM; Schweizer L; Steinbacher TE; Schumacher WA; Robl JA; Macor JE; Atwal KS; Stein PD
Bioorg Med Chem Lett; 2011 Dec; 21(24):7516-21. PubMed ID: 22041058
[TBL] [Abstract][Full Text] [Related]
17. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa.
Hara T; Yokoyama A; Ishihara H; Yokoyama Y; Nagahara T; Iwamoto M
Thromb Haemost; 1994 Mar; 71(3):314-9. PubMed ID: 8029795
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ
J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248
[TBL] [Abstract][Full Text] [Related]
19. Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.
Shi Y; Sitkoff D; Zhang J; Han W; Hu Z; Stein PD; Wang Y; Kennedy LJ; O'Connor SP; Ahmad S; Liu EC; Seiler SM; Lam PY; Robl JA; Macor JE; Atwal KS; Zahler R
Bioorg Med Chem Lett; 2007 Nov; 17(21):5952-8. PubMed ID: 17855089
[TBL] [Abstract][Full Text] [Related]
20. Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications.
Qiao JX; Wang TC; Wang GZ; Cheney DL; He K; Rendina AR; Xin B; Luettgen JM; Knabb RM; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2007 Sep; 17(18):5041-8. PubMed ID: 17643988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
